202 related articles for article (PubMed ID: 30377888)
1. Modeling near-continuous clinical endpoint as categorical: application to longitudinal exposure-response modeling of Mayo scores for golimumab in patients with ulcerative colitis.
Hu C; Adedokun OJ; Zhang L; Sharma A; Zhou H
J Pharmacokinet Pharmacodyn; 2018 Dec; 45(6):803-816. PubMed ID: 30377888
[TBL] [Abstract][Full Text] [Related]
2. Facilitating Longitudinal Exposure-Response Modeling of a Composite Endpoint Using the Joint Modeling of Sparsely and Frequently Collected Subcomponents.
Hu C; Zhou H; Sharma A
AAPS J; 2020 May; 22(4):79. PubMed ID: 32700158
[TBL] [Abstract][Full Text] [Related]
3. Latent variable indirect response modeling of clinical efficacy endpoints with combination therapy: application to guselkumab and golimumab in patients with ulcerative colitis.
Hu C; Vetter M; Vermeulen A; Ouellet D
J Pharmacokinet Pharmacodyn; 2023 Apr; 50(2):133-144. PubMed ID: 36648595
[TBL] [Abstract][Full Text] [Related]
4. Improvement in latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint in rheumatoid arthritis.
Hu C; Zhou H
J Pharmacokinet Pharmacodyn; 2016 Feb; 43(1):45-54. PubMed ID: 26553114
[TBL] [Abstract][Full Text] [Related]
5. Improvement in latent variable indirect response modeling of multiple categorical clinical endpoints: application to modeling of guselkumab treatment effects in psoriatic patients.
Hu C; Randazzo B; Sharma A; Zhou H
J Pharmacokinet Pharmacodyn; 2017 Oct; 44(5):437-448. PubMed ID: 28634654
[TBL] [Abstract][Full Text] [Related]
6. Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis.
Rutgeerts P; Feagan BG; Marano CW; Padgett L; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Zhang H; Colombel JF; Reinisch W; Gibson PR; Sandborn WJ;
Aliment Pharmacol Ther; 2015 Sep; 42(5):504-14. PubMed ID: 26119226
[TBL] [Abstract][Full Text] [Related]
7. Joint longitudinal model development: application to exposure-response modeling of ACR and DAS scores in rheumatoid arthritis patients treated with sirukumab.
Hu C; Xu Y; Zhuang Y; Hsu B; Sharma A; Xu Z; Zhang L; Zhou H
J Pharmacokinet Pharmacodyn; 2018 Oct; 45(5):679-691. PubMed ID: 29961161
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
[TBL] [Abstract][Full Text] [Related]
9. Challenges in longitudinal exposure-response modeling of data from complex study designs: a case study of modeling CDAI score for ustekinumab in patients with Crohn's disease.
Hu C; Adedokun OJ; Chen Y; Szapary PO; Gasink C; Sharma A; Zhou H
J Pharmacokinet Pharmacodyn; 2017 Oct; 44(5):425-436. PubMed ID: 28623612
[TBL] [Abstract][Full Text] [Related]
10. Latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint.
Hu C; Szapary PO; Mendelsohn AM; Zhou H
J Pharmacokinet Pharmacodyn; 2014 Aug; 41(4):335-49. PubMed ID: 25038623
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics and Exposure-Response Modeling Analyses of Golimumab in Children With Moderately to Severely Active Ulcerative Colitis.
Xu Y; Adedokun OJ; Chan D; Hu C; Xu Z; Strauss RS; Hyams JS; Turner D; Zhou H
J Clin Pharmacol; 2019 Apr; 59(4):590-604. PubMed ID: 30536638
[TBL] [Abstract][Full Text] [Related]
12. Latent variable indirect response modeling of categorical endpoints representing change from baseline.
Hu C; Xu Z; Mendelsohn AM; Zhou H
J Pharmacokinet Pharmacodyn; 2013 Feb; 40(1):81-91. PubMed ID: 23275019
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.
Adedokun OJ; Xu Z; Marano CW; Strauss R; Zhang H; Johanns J; Zhou H; Davis HM; Reinisch W; Feagan BG; Rutgeerts P; Sandborn WJ
J Crohns Colitis; 2017 Jan; 11(1):35-46. PubMed ID: 27440869
[TBL] [Abstract][Full Text] [Related]
14. Improving categorical endpoint longitudinal exposure-response modeling through the joint modeling with a related endpoint.
Hu C; Zhou H
J Pharmacokinet Pharmacodyn; 2022 Jun; 49(3):283-291. PubMed ID: 34800232
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Rutgeerts P;
Gastroenterology; 2014 Jan; 146(1):96-109.e1. PubMed ID: 23770005
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetics and Exposure-Response Modeling of Golimumab in Adults With Moderately to Severely Active Ulcerative Colitis.
Adedokun OJ; Xu Z; Liao S; Strauss R; Reinisch W; Feagan BG; Sandborn WJ
Clin Ther; 2020 Jan; 42(1):157-174.e4. PubMed ID: 31982148
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetics and Exposure-Response Modeling Analyses of Ustekinumab in Adults With Moderately to Severely Active Ulcerative Colitis.
Xu Y; Hu C; Chen Y; Miao X; Adedokun OJ; Xu Z; Sharma A; Zhou H
J Clin Pharmacol; 2020 Jul; 60(7):889-902. PubMed ID: 32026499
[TBL] [Abstract][Full Text] [Related]
18. Agreement Between Rectosigmoidoscopy and Colonoscopy Analyses of Disease Activity and Healing in Patients With Ulcerative Colitis.
Colombel JF; Ordás I; Ullman T; Rutgeerts P; Chai A; O'Byrne S; Lu TT; Panés J
Gastroenterology; 2016 Feb; 150(2):389-95.e3. PubMed ID: 26526713
[TBL] [Abstract][Full Text] [Related]
19. A latent variable approach for modeling categorical endpoints among patients with rheumatoid arthritis treated with golimumab plus methotrexate.
Hu C; Xu Z; Rahman MU; Davis HM; Zhou H
J Pharmacokinet Pharmacodyn; 2010 Aug; 37(4):309-21. PubMed ID: 20635122
[TBL] [Abstract][Full Text] [Related]
20. A review of infliximab use in ulcerative colitis.
Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
